183 related articles for article (PubMed ID: 9593067)
1. Positive inotropic effects of the novel Na+-channel modulator BDF 9198 in human nonfailing and failing myocardium.
Müller-Ehmsen J; Brixius K; Schwinger RH
J Cardiovasc Pharmacol; 1998 May; 31(5):684-9. PubMed ID: 9593067
[TBL] [Abstract][Full Text] [Related]
2. Increase in force of contraction by activation of the Na+/Ca(2+)-exchanger in human myocardium.
Müller-Ehmsen J; Frank K; Brixius K; Schwinger RH
Br J Clin Pharmacol; 1997 Apr; 43(4):399-405. PubMed ID: 9146852
[TBL] [Abstract][Full Text] [Related]
3. Effect of inotropic interventions on the force-frequency relation in the human heart.
Bavendiek U; Brixius K; Münch G; Zobel C; Müller-Ehmsen J; Schwinger RH
Basic Res Cardiol; 1998; 93 Suppl 1():76-85. PubMed ID: 9833134
[TBL] [Abstract][Full Text] [Related]
4. Enantioselective inotropic actions of the Na+-channel activators BDF 9148, BDF 9196 and BDF 9167 in human failing and nonfailing myocardium.
Schwinger RH; Müller-Ehmsen J; Böhm M; Erdmann E
J Pharmacol Exp Ther; 1996 Mar; 276(3):1180-8. PubMed ID: 8786551
[TBL] [Abstract][Full Text] [Related]
5. Evidence for a sustained effectiveness of sodium-channel activators in failing human myocardium.
Schwinger RH; Böhm M; Mittmann C; La Rosée K; Erdmann E
J Mol Cell Cardiol; 1991 Apr; 23(4):461-71. PubMed ID: 1658340
[TBL] [Abstract][Full Text] [Related]
6. Na(+)-channel activators increase cardiac glycoside sensitivity in failing human myocardium.
Schwinger RH; Böhm M; La Rosée K; Schmidt U; Schulz C; Erdmann E
J Cardiovasc Pharmacol; 1992 Apr; 19(4):554-61. PubMed ID: 1380598
[TBL] [Abstract][Full Text] [Related]
7. Effect of inotropic stimulation on the negative force-frequency relationship in the failing human heart.
Schwinger RH; Böhm M; Müller-Ehmsen J; Uhlmann R; Schmidt U; Stäblein A; Uberfuhr P; Kreuzer E; Reichart B; Eissner HJ
Circulation; 1993 Nov; 88(5 Pt 1):2267-76. PubMed ID: 8222121
[TBL] [Abstract][Full Text] [Related]
8. Na+-channel modulating effect of the inotropic compound S(-)BDF 9196 in human myocardium.
Müller-Ehmsen J; Näbauer M; Schwinger RH
Naunyn Schmiedebergs Arch Pharmacol; 1999 Jan; 359(1):60-4. PubMed ID: 9933152
[TBL] [Abstract][Full Text] [Related]
9. Comparison of the action potential prolonging and positive inotropic activity of DPI 201-106 and BDF 9148 in human ventricular myocardium.
Hoey A; Amos GJ; Ravens U
J Mol Cell Cardiol; 1994 Aug; 26(8):985-94. PubMed ID: 7799453
[TBL] [Abstract][Full Text] [Related]
10. Subsensitivity of the failing human heart to isoprenaline and milrinone is related to beta-adrenoceptor downregulation.
Böhm M; Diet F; Feiler G; Kemkes B; Kreuzer E; Weinhold C; Erdmann E
J Cardiovasc Pharmacol; 1988 Dec; 12(6):726-32. PubMed ID: 2467092
[TBL] [Abstract][Full Text] [Related]
11. Enhanced sensitivity of the failing human myocardium to cardiac glycosides and Na(+)-channel activators.
Schwinger RH; Müller-Ehmsen J; Frank K; Koch A; Erdmann E
Am Heart J; 1996 May; 131(5):988-93. PubMed ID: 8615321
[TBL] [Abstract][Full Text] [Related]
12. Effect of the Na+-channel modulator BDF 9148 on Ca2+-sensitivity and force of contraction of hypertrophic myocardium from transgene rats harboring the mouse Renin gene (TG(mREN2)27).
Zobel C; Brixius K; Frank K; Schwinger RH
Naunyn Schmiedebergs Arch Pharmacol; 1998 May; 357(5):532-9. PubMed ID: 9650806
[TBL] [Abstract][Full Text] [Related]
13. Evidence for functional relevance of an enhanced expression of the Na(+)-Ca2+ exchanger in failing human myocardium.
Flesch M; Schwinger RH; Schiffer F; Frank K; Südkamp M; Kuhn-Regnier F; Arnold G; Böhm M
Circulation; 1996 Sep; 94(5):992-1002. PubMed ID: 8790037
[TBL] [Abstract][Full Text] [Related]
14. Altered inotropism in the failing human myocardium.
Bavendiek U; Brixius K; Frank K; Reuter H; Pietsch M; Gross A; Müller-Ehmsen J; Erdmann E; Schwinger RH
Basic Res Cardiol; 1996; 91 Suppl 2():9-16. PubMed ID: 8957538
[TBL] [Abstract][Full Text] [Related]
15. EMD 53998 acts as Ca(2+)-sensitizer and phosphodiesterase III-inhibitor in human myocardium.
Uhlmann R; Schwinger RH; Lues I; Erdmann E
Basic Res Cardiol; 1995; 90(5):365-71. PubMed ID: 8585857
[TBL] [Abstract][Full Text] [Related]
16. Mechanism underlying the reduced positive inotropic effects of the phosphodiesterase III inhibitors pimobendan, adibendan and saterinone in failing as compared to nonfailing human cardiac muscle preparations.
von der Leyen H; Mende U; Meyer W; Neumann J; Nose M; Schmitz W; Scholz H; Starbatty J; Stein B; Wenzlaff H
Naunyn Schmiedebergs Arch Pharmacol; 1991 Jul; 344(1):90-100. PubMed ID: 1723153
[TBL] [Abstract][Full Text] [Related]
17. Effects of cantharidin on force of contraction and phosphatase activity in nonfailing and failing human hearts.
Linck B; Boknik P; Knapp J; Müller FU; Neumann J; Schmitz W; Vahlensieck U
Br J Pharmacol; 1996 Oct; 119(3):545-50. PubMed ID: 8894176
[TBL] [Abstract][Full Text] [Related]
18. Influence of forskolin on the force-frequency behavior in nonfailing and end-stage failing human myocardium.
Pieske B; Trost S; Schütt K; Minami K; Just H; Hasenfuss G
Basic Res Cardiol; 1998; 93 Suppl 1():66-75. PubMed ID: 9833133
[TBL] [Abstract][Full Text] [Related]
19. Reduced sodium pump alpha1, alpha3, and beta1-isoform protein levels and Na+,K+-ATPase activity but unchanged Na+-Ca2+ exchanger protein levels in human heart failure.
Schwinger RH; Wang J; Frank K; Müller-Ehmsen J; Brixius K; McDonough AA; Erdmann E
Circulation; 1999 Apr; 99(16):2105-12. PubMed ID: 10217649
[TBL] [Abstract][Full Text] [Related]
20. Positive inotropic responses of the sodium channel modulator BDF 9148 in diseased rat myocardium.
Hoey A; Nankervis R; Brown L
Clin Exp Pharmacol Physiol; 1995; 22(6-7):418-22. PubMed ID: 8582092
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
